Therapeutic Antibodies

Degeneration of dopaminergic neuron in Parkinson's disease
#BioArctic #Monoclonal antibodies #Neuroscience #Parkinson's #Phase II trial

Clinical trial will test monoclonal antibody in Parkinson’s disease

BioArctic says it has dosed the first patient with exidavnemab in the EXIST Phase IIa study in Parkinson’s disease patients.   Exidavnemab is a monoclonal antibody designed to target aggregated forms of the protein α-synuclein, believed to play a role in the disease progression in different neurological disorders… Read More

#News

Antibody drug conjugate
#Allink Biotherapeutics #Antibody drug conjugate (ADC) #Bispecific Antibodies #Financing

Allink raises $42m for bispecific antibody and ADC pipeline

Biotechnology company Allink Biotherapeutics has successfully completed a $42 million Series A financing.   The financing round was led by Lanchi Ventures, with participation new investors including Yuanbio Venture Capital, Legend Capital and C&D Emerging Industry Equity Investment, alongside strong support from existing shareholders Gaorong Ventures and Med-Fine Capital.  "Since our… Read More

#Business & Investment #News

Monoclonal antibodies
#Ark Biopharmaceutical #Monoclonal antibodies #Phase I trial #Respiratory syncytial virus #Virology

Potential monoclonal antibody to prevent RSV enters human trials

Ark Biopharmaceutical (ArkBio) says it has successfully dosed all participants in a Phase I clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection.  The treatment offers a potential a new option for preventing RSV infection for vulnerable infants susceptible… Read More

#News

FDA
#Bispecific Antibodies #FDA #Jazz Pharmaceuticals #Oncology

Bispecific antibody gets accelerated FDA approval for biliary tract cancer

The Food and Drug Administration (FDA) has granted accelerated approval to Jazz Pharmacuticals’ zanidatamab-hrii (Ziihera) a bispecific HER2-directed antibody.  It is approved for previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.  The FDA also approved VENTANA PATHWAY anti-HER-2/neu (4B5) Rabbit… Read More

#News #Regulatory

Bispecific antibodies
#Antibodies #Antibody engineering #Bispecific Antibodies #EpiBiologics #PEGS Europe

Data shows disease-selective extracellular protein degradation 

EpiBiologics presented new data demonstrating the unique capabilities of its EpiTAC platform at the 16th Annual PEGS Europe conference (November 5-7, 2024 in Barcelona, Spain) and the 2024 Antibody Engineering and will be presenting again at Therapeutics US conference (December 15-18, 2024 in San Diego, California).  … Read More

#News

#Antibody #Antibody libraries #Drug development #Drug discovery #Monoclonal antibodies

A pioneering approach to biotherapeutic antibody discovery 

This is a paid-for advertorial by BIO-RAD. Immunotherapy has revolutionised cancer treatment, yet the drug discovery process to develop new biotherapeutic antibodies remains arduous. However, significant advances in antibody technology such as phage display have enabled fully human antibodies to be developed from animal-free libraries for just about any antigen. … Read More

#Exclusive Content

Antibodies
#Antiverse #Artificial intelligence (AI) #Collaboration #GPCRs #Nxera Pharma #Therapeutic Antibodies

Partners set out to design GPCR-targeted antibodies using AI

A new multi-target partnership aims meet unmet need by designing antibodies for G-protein coupled receptors (GPCRs). The collaboration will combine Antiverse’s generative AI antibody design expertise, including its proprietary machine-learning-generated ‘epitope-specific libraries’, with Nxera’s NxWave platform for GPCR target selection, validation and structural determination. The partnership hopes to bring transformative… Read More

#Business & Investment #News

EMA
#European Medicines Agency #Monoclonal antibodies #Paediatrics #Phase III trial #Regeneron Pharmaceuticals #Sanofi

EU Dupixent use extended to children with eosinophilic esophagitis

The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year old. The approval is limited to children aged one to 11 years who weigh at least 15kg and who are inadequately controlled by, intolerant to, or who are not candidates… Read More

#News #Regulatory

Weight loss concept
#Mouse models #Obesity #Skye Bioscience #Therapeutic Antibodies #Weight loss

Significant weight loss with novel CB1-inhibiting antibody

Skye Bioscience has announced preliminary data from a diet-induced obesity (DIO) model in mice, in which its CB1-inhibiting antibody, nimacimab, achieved dose-dependent weight loss of up to 16% compared to vehicle. Skye developed a DIO model using a transgenic mouse expressing the human CB1 receptor… Read More

#News

#Artificial intelligence (AI) #Cancer research #Immunotherpy #Oncology #Radiopharmaceuticals #Therapeutic Antibodies

What lies ahead in cancer research?

Megan Thomas comments and speaks with experts to uncover the future of cancer research. Artificial intelligence (AI) It’s not whether AI should be used, it’s when and how. Until several hurdles are overcome, such as data quality, data privacy and security, as well as regulatory and ethical challenges, this is… Read More

#Cancer Research #Exclusive Content

Human liver
#Cardiometabolic diseases #GLP-1 #Monoclonal antibodies #Obesity #Tiziana Life Sciences

Ozempic and antibody combination restores liver homeostasis

New study results have demonstrated the anti-inflammatory potential of Tiziana Life Sciences’ anti-CD3 antibody foralumab in combination with semaglutide (Ozempic/Wegovy). The data show that the combination of nasal anti-CD3 plus semaglutide improves liver homeostasis and reduces inflammation in models of diet-induced obesity (DIO). Read More

#News

Antibodies
#Immunotherapy #Interview #Monoclonal antibodies #Oncology #Therapeutic Antibodies

The new wave: Creating next-gen antibody therapies

Diana Spencer speaks to Dr Wansu Qiu, Technical Account Manager at Sino Biological US, about how advances in engineering technologies are paving the way for improved antibody drugs. DS: Since 1986, the FDA has granted marketing authorisation to over 100 therapeutic antibodies, many in oncology. Why has this been a… Read More

#Exclusive Content #Opinion

Non-small cell lung cancer
#Lung cancer #Monoclonal antibodies #Oncology #Phase I trial #Pierre Fabre

Trial assesses new approach to NSCLC with MET alterations

The first patient has been dosed with PFL-002/VERT-002 in a Phase I/II first-in-human trial for patients with non-small cell lung cancer (NSCLC) with MET alterations. PFL-002/VERT-002 is a monoclonal antibody acting as a degrader of c-MET. MET, also known as hepatocyte growth factor receptor… Read More

#Cancer Research #News

Monoclonal antibody
#Cancer Research UK #Clinical trial #Monoclonal antibodies #Oncology #UCB

Monoclonal antibody targets HLA-G in advanced cancers

A new clinical trial has launched to assess monoclonal antibody UCB4594 in people with advanced cancers. The first site for the study has opened at the National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility (CRF) at The Christie NHS Foundation Trust (The… Read More

#Cancer Research #News

Dementia
#Alzheimer's #Drug development #Eli Lilly #Monoclonal antibodies #National Institute for Health and Care Excellence (NICE) #Regulatory

UK’s NICE rejects second disease-modifying therapy for Alzheimer’s 

UK regulator the National Institute for Health and Care Excellence (NICE) has ruled against the use of a second monoclonal antibody for Alzheimer’s disease, just two months after rejecting Eisai’s lecanemab (Leqembi).  NICE concluded that Eli Lilly’s donanemab (Kisunla) only provides a “small benefit”… Read More

#News

Monoclonal antibody
#Antibody #Biotherapeutics #Therapeutic Antibodies #Tumour biology

Tumour infiltrating B cells are a source of new targets and therapeutics  

Recent research is shedding light on the crucial role of B cells in the fight against cancer, opening exciting new avenues for therapeutic development, according to Stefano Gullà, Chief Scientific Officer at Kling Biotherapeutics.  Cancer immunotherapies have been raising the bar for standard of care in oncology for more than… Read More

#Exclusive Content